Post covid 19 pulmonary fibrosis. Is it real threat?
- PMID: 34099197
- PMCID: PMC7654356
- DOI: 10.1016/j.ijtb.2020.11.003
Post covid 19 pulmonary fibrosis. Is it real threat?
Abstract
After the COVID-19 outbreak, increasing number of patients worldwide who have survived COVID-19 continue to battle the symptoms of the illness, long after they have been clinically tested negative for the disease. As we battle through this pandemic, the challenging part is to manage COVID-19 sequelae which may vary from fatigue and body aches to lung fibrosis. This review addresses underlying mechanism, risk factors, course of disease and treatment option for post covid pulmonary fibrosis. Elderly patient who require ICU care and mechanical ventilation are at the highest risk to develop lung fibrosis. Currently, no fully proven options are available for the treatment of post inflammatory COVID 19 pulmonary fibrosis.
Keywords: ARDS; Antifibrotic; Covid 19; Pulmonary fibrosis.
Copyright © 2020 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflicts of interest The authors have none to declare.
Similar articles
-
The Management of Pulmonary Fibrosis in COVID-19.Acta Med Indones. 2021 Apr;53(2):233-241. Acta Med Indones. 2021. PMID: 34251354 Review.
-
Clinical characteristics and outcomes of post-COVID-19 pulmonary fibrosis: A case-control study.Medicine (Baltimore). 2022 Jan 21;101(3):e28639. doi: 10.1097/MD.0000000000028639. Medicine (Baltimore). 2022. PMID: 35060549 Free PMC article.
-
Pulmonary fibrosis secondary to COVID-19: a narrative review.Expert Rev Respir Med. 2021 Jun;15(6):791-803. doi: 10.1080/17476348.2021.1916472. Epub 2021 Apr 27. Expert Rev Respir Med. 2021. PMID: 33902377 Review.
-
Pulmonary fibrosis followed by severe pneumonia in patients with COVID-19 infection requiring mechanical ventilation: a prospective multicentre study.BMJ Open Respir Res. 2024 Oct 4;11(1):e002538. doi: 10.1136/bmjresp-2024-002538. BMJ Open Respir Res. 2024. PMID: 39366721 Free PMC article.
-
[Pulmonary fibrosis in patients with COVID-19: A review].Ter Arkh. 2022 Dec 26;94(11):1333-1339. doi: 10.26442/00403660.2022.11.201943. Ter Arkh. 2022. PMID: 37167174 Review. Russian.
Cited by
-
Pathophysiology of Post-COVID syndromes: a new perspective.Virol J. 2022 Oct 9;19(1):158. doi: 10.1186/s12985-022-01891-2. Virol J. 2022. PMID: 36210445 Free PMC article. Review.
-
Post-COVID-19 Pulmonary Fibrosis: Facts-Challenges and Futures: A Narrative Review.Pulm Ther. 2023 Sep;9(3):295-307. doi: 10.1007/s41030-023-00226-y. Epub 2023 May 20. Pulm Ther. 2023. PMID: 37209374 Free PMC article. Review.
-
Quantification of fibrosis extend and airspace availability in lung: A semi-automatic ImageJ/Fiji toolbox.PLoS One. 2024 Feb 29;19(2):e0298015. doi: 10.1371/journal.pone.0298015. eCollection 2024. PLoS One. 2024. PMID: 38421996 Free PMC article.
-
Therapeutic and prophylactic effect of flavonoids in post-COVID-19 therapy.Phytother Res. 2022 May;36(5):2042-2060. doi: 10.1002/ptr.7436. Epub 2022 Mar 18. Phytother Res. 2022. PMID: 35302260 Free PMC article. Review.
-
Lung Fibrosis after COVID-19: Treatment Prospects.Pharmaceuticals (Basel). 2021 Aug 17;14(8):807. doi: 10.3390/ph14080807. Pharmaceuticals (Basel). 2021. PMID: 34451904 Free PMC article. Review.
References
-
- Istituto Superiore Sanità . 2020. Sorveglianza Integrata COVID-19 in Italia.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials